Reviva Pharmaceuticals Holdings, Inc. (RVPH)
Reviva Pharmaceuticals Holdings, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Cupertino, CA, US. The stock last traded at $0.46, up 2.22% on the session, giving a market capitalisation of $5.9M. On trailing twelve-month figures it carries a trailing P/E of -0.05, a net margin of 0.0%. Its beta of 0.49 implies it has historically moved less than the broad market.
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company’s lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer’s disease, and Parkinson’s disease psychosis. It also engages in the clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis. In addition, the company is in preclinical development for the treatment of psoriasis; and RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.
Reviva Pharmaceuticals Holdings, Inc. is most often compared with the following Healthcare names: